Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an ...
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls ...
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results